Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

C7912

Sigma-Aldrich

Cefotaxime sodium salt

potency: 916-964 μg per mg

Synonyme(s) :

Cefotaxime, Cefotaxim sodium salt

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule empirique (notation de Hill):
C16H16N5NaO7S2
Numéro CAS:
Poids moléculaire :
477.45
Numéro Beilstein :
5711411
Numéro CE :
Numéro MDL:
Code UNSPSC :
51284136
ID de substance PubChem :
Nomenclature NACRES :
NA.85

Forme

powder

Puissance

916-964 μg per mg

Solubilité

H2O: 50 mg/mL

Spectre d'activité de l'antibiotique

Gram-negative bacteria
Gram-positive bacteria

Mode d’action

cell wall synthesis | interferes

Température de stockage

2-8°C

Chaîne SMILES 

[Na+].[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\c3csc(N)n3)C([O-])=O

InChI

1S/C16H17N5O7S2.Na/c1-6(22)28-3-7-4-29-14-10(13(24)21(14)11(7)15(25)26)19-12(23)9(20-27-2)8-5-30-16(17)18-8;/h5,10,14H,3-4H2,1-2H3,(H2,17,18)(H,19,23)(H,25,26);/q;+1/p-1/b20-9-;/t10-,14-;/m1./s1

Clé InChI

AZZMGZXNTDTSME-JUZDKLSSSA-M

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

Chemical structure: ß-lactam

Application

Cefotaxim has been used to find new residues involved in cefotaxime hydrolysis in CTX-M β-lactamases, to study antibiotic-susceptible and -resistant Streptococcus pneumoniae infections, and to study pneumococcal pneumonia and the pharmokinetics of various treatments. It may be used to study the effects of binding and inhibition of penicillin binding protein 2 (PBP2) on bacterial mucopeptide synthesis.

Actions biochimiques/physiologiques

Cefotaxim inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls. As a result, bacteria lyse due to cell wall autolytic enzymes.

Autres remarques

Broad spectrum third generation cephalosporin antibiotic.
Keep container tightly closed in a dry and well-ventilated place.

Pictogrammes

Health hazard

Mention d'avertissement

Danger

Mentions de danger

Classification des risques

Resp. Sens. 1 - Skin Sens. 1

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

dust mask type N95 (US), Eyeshields, Faceshields, Gloves


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

F Soriano et al.
The Journal of antimicrobial chemotherapy, 38(2), 227-236 (1996-08-01)
In an attempt to determine the susceptibility breakpoints for amoxycillin, co-amoxiclav and cefotaxime in pneumococcal pneumonia, a neutropenic mouse model was established and tested with two strains having different susceptibility to penicillins and cefotaxime. With a penicillin-sensitive strain (MIC/MBC =
Francisco José Pérez-Llarena et al.
Antimicrobial agents and chemotherapy, 55(9), 4361-4368 (2011-07-07)
The CTX-M β-lactamases are an increasingly prevalent group of extended-spectrum β-lactamases (ESBL). Point mutations in CTX-M β-lactamases are considered critical for enhanced hydrolysis of cefotaxime. In order to clarify the structural determinants of the activity against cefotaxime in CTX-M β-lactamases
Violeta Rodríguez-Cerrato et al.
The Journal of antimicrobial chemotherapy, 60(5), 1159-1162 (2007-09-11)
In an innovative therapeutic exploitation against antibiotic-resistant Streptococcus pneumoniae, here we have evaluated the in vitro activity of a purified bacterially-encoded cell wall lytic enzyme, LytA (the major pneumococcal autolysin), and compared it with those of Cpl-1 and Pal (pneumococcal
Martijn F Schenk et al.
PLoS genetics, 8(6), e1002783-e1002783 (2012-07-05)
For a quantitative understanding of the process of adaptation, we need to understand its "raw material," that is, the frequency and fitness effects of beneficial mutations. At present, most empirical evidence suggests an exponential distribution of fitness effects of beneficial
Katrine Hartung Hansen et al.
Applied and environmental microbiology, 79(3), 794-798 (2012-11-20)
Current knowledge on extended-spectrum beta-lactamases (ESBLs) in animals is based largely on cross-sectional studies and qualitative data. The aim of this longitudinal study was to elucidate carriage proportions and fecal counts of ESBL-producing Escherichia coli in pigs during the production

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique